A Message from the President
Earlier this month, the Society for Immunotherapy of Cancer (SITC) held its 32nd Annual Meeting & Pre-Conference Programs, the society's most highly attended event in its history.
More than 3,500 delegates converged on National Harbor, MD, Nov. 8-12, a 30 percent increase over last year's meeting (which had broken previous records). The large increase in abstracts submitted (up 21 percent) necessitated additional concurrent sessions to allow for the important new data to be highlighted. All of the meeting organizers, chairs, speakers and attendees ensured that the meeting had the highest level of scientific exchange of the latest advances in cancer immunotherapy research.
I'd like to personally thank the program organizers who created the vision, the faculty members who presented, the abstract presenters who brought the latest data, and particularly to the SITC staff who worked tirelessly to ensure each participant had a positive experience – making this meeting our society's most successful yet. From the industry program on biomarkers that kicked off the Pre-Conference Programs through this year's exciting Hot Topic Symposium on how physics and mathematics can impact progress in our field's research, I was proud of the caliber of programming SITC 2017 offered to delegates. Lastly, I was really pleased with the networking opportunities for researchers involved in the Early Career Scientist Committee, the 2nd World Immunotherapy Council Young Investigator Symposium, the SITC Sparkathon, as well as the Women's Reception – opportunities that ensure SITC supports all of its members with scientific and career growth opportunities.
We already have big plans for the 2018 Annual Meeting – which include a venue change to the Walter E. Washington Convention Center in Washington D.C., Nov. 7-11. Stay tuned in the months to come for more details on these programs.
I'd like to acknowledge the incredible response received in new and renewed memberships at the SITC Membership Resource Booth during the 32nd Annual Meeting. SITC continuously strives to ensure members are receiving the value they want and need from their membership. As a thank you to our members who seek to advance cancer immunotherapy research, SITC is pleased to waive article processing charges for members on manuscripts accepted through 2018 to the Journal for ImmunoTherapy of Cancer (JITC), the society's official open access journal covering all aspects of tumor immunology and cancer immunotherapy – from basic science to clinical application. Now through March 2, JITC welcomes submissions for a special series on the topics of Emerging Immunotherapeutic Agents, New Regulatory Approvals in Cancer Immunotherapy, and Challenges in Clinical Management.
Learn more about the many benefits of becoming a SITC member today.
Lisa H. Butterfield, PhD